Theralink Technologies Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
THER Over the counter 8731 https://oncbiomune.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Theralink Technologies Inc

Theralink® Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company - May 23rd, 2023 12:30 pm
Theralink® Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University - Apr 3rd, 2023 12:30 pm
Theralink® Technologies Begins Receiving Payments from Third Party Payors for its Advanced Breast Cancer Assay, Achieving Key Milestone - Feb 23rd, 2023 1:30 pm
Theralink's Exclusive Licensed RPPA Technology for Commercial Laboratory Testing to Assist the White House Cancer Moonshot Initiative - Jan 17th, 2023 1:30 pm
Theralink® Technologies Appoints Michael Vallone as Senior Director of Commercialization - Jan 9th, 2023 1:00 pm
Theralink® Technologies Appoints Seasoned Commercial Leader, Faith Zaslavsky, as President & Chief Operating Officer for its Precision Oncology Company - Dec 6th, 2022 1:30 pm
Theralink® Technologies Accepted to Present Two Posters at the Upcoming San Antonio Breast Cancer Symposium - Dec 1st, 2022 1:30 pm
Theralink® Technologies Announces Closing of Private Placement and Conversion of Existing Convertible Notes and Convertible Preferred Shares - Nov 29th, 2022 9:15 pm
Theralink® Technologies Achieves the First College of American Pathologists Accreditation for a Commercial Reverse Phase Protein Array Laboratory in U.S. - Nov 28th, 2022 1:30 pm
Theralink® Technologies Receives Final Medicare Reimbursement Rate Determination and PTAN Enrollment - Nov 14th, 2022 1:00 pm
Theralink® Technologies Appoints Dr. Mattia Cremona as its Director of its Biopharma Laboratory - Nov 7th, 2022 1:30 pm
Theralink Technologies to Participate in the LD Micro Main Event Conference on October 25-27 - Oct 11th, 2022 12:00 pm
Theralink® Technologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14 - Sep 7th, 2022 12:30 pm
Theralink® Acquires Two New Milestone Patents Relating to Methods for Treating Breast Cancer - Jul 25th, 2022 12:30 pm
Theralink® Technologies to Host Fireside Chat with Dr. Mick Ruxin, President and Chief Executive Officer, on June 22nd at 11:00 a.m. ET - Jun 15th, 2022 11:30 am